Proton Pump Inhibitor Induced Hypomagnesemia

Proton Pump Inhibitor Induced Hypomagnesemia - PPI induced hypomagnesemia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35945

Enrollment

200

Registered

2011-10-07

Start date

2012-03-15

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypomagnesemia low magnesium level

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Usage of gastric acid blockers of the class of PPI's (Proton Pump Inhibitors). These are mainly the group of the so called "Dyspepsia" patients.

Exclusion criteria

Exclusion criteria: (a) Short bowel patients are excluded, because they have a malabsorptional status of their intestinal tract. (b) Individuals with known alcoholism, because alcohol abuse can produce hypomagnesemia. (c) Individuals with: Unregulated diabetes mellitus, syndrome of Gitelman, syndrome of Bartter, anemia, strong adipositas or strong anorexia. (d) For a more exact list please refer to the study protocol

Design outcomes

Primary

Measure	Time frame
(a) Primary blood variable: Serum magnesium in clot- or haparin-blood. Measurement via calorimetric xylidyl blue method (Roche). - a value 0.84 mmol/l is considered to be hypermagnesemia (b) Genetic analysis: This analysis is a "whole genome SNP array". Possible variations in the SNiPs may be unveiled by a comparison with a standard database. A limit value that identifies a variation to be significant is dependent on the analysis method.In general correlation peaks with a hight > 0.5 indicate possible interesting areas of the genome and may be closer investigated in further in vitro or in vivio models. The SNP analysis will be performed as soon as a number of hypomagnesemic PPI users are identified.	—

Measure

Time frame

(a) Primary blood variable: Serum magnesium in clot- or haparin-blood. Measurement via calorimetric xylidyl blue method (Roche). - a value 0.84 mmol/l is considered to be hypermagnesemia (b) Genetic analysis: This analysis is a "whole genome SNP array". Possible variations in the SNiPs may be unveiled by a comparison with a standard database. A limit value that identifies a variation to be significant is dependent on the analysis method.In general correlation peaks with a hight > 0.5 indicate possible interesting areas of the genome and may be closer investigated in further in vitro or in vivio models. The SNP analysis will be performed as soon as a number of hypomagnesemic PPI users are identified.

—

Secondary

Measure	Time frame
(a) Secondary blood variabele: Serum calcium in clot- or heparin-blood - a value 2,31 mmol/L is hypercalcemia	—

Countries

Netherlands

Outcome results